Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study ; volume:9 ; number:1 ; day:18 ; month:9 ; year:2009 ; pages:1-11 ; date:12.2009
BMC cancer ; 9, Heft 1 (18.9.2009), 1-11, 12.2009
- Creator
-
Emery, Ivette F.
- Contributor
-
Battelli, Chiara
Auclair, Paul L.
Carrier, Kathleen
Hayes, Daniel M.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-9-333
- URN
-
urn:nbn:de:1111-2016030351134
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.0008, 6:35 AM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Emery, Ivette F.
- Battelli, Chiara
- Auclair, Paul L.
- Carrier, Kathleen
- Hayes, Daniel M.
- SpringerLink (Online service)
Other Objects (12)
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis
Treatment with gefitinib after erlotinib-induced liver injury: a case report
Entwicklung einer medikamentenfreisetzenden Intraokularlinse mit den EGFR-Inhibitoren Erlotinib und Gefitinib
Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer – a retrospective analysis: JMTO LC03-02
Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis
Treatment with gefitinib after erlotinib-induced liver injury: a case report
Entwicklung einer medikamentenfreisetzenden Intraokularlinse mit den EGFR-Inhibitoren Erlotinib und Gefitinib
Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer – a retrospective analysis: JMTO LC03-02
Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Targeting KCa3.1 channels to overcome erlotinib resistance in non-small cell lung cancer cells
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis
Treatment with gefitinib after erlotinib-induced liver injury: a case report
Entwicklung einer medikamentenfreisetzenden Intraokularlinse mit den EGFR-Inhibitoren Erlotinib und Gefitinib
Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer – a retrospective analysis: JMTO LC03-02
Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment
Targeting KCa3.1 to overcome erlotinib resistance in non-small cell lung cancer cells
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship